Chalothorn Wannaphut: Our meta-analysis on SGLT2 inhibitors in cancer patients receiving anthracycline
Chalothorn “Sai” Wannaphut, Internal Medicine Resident at John A. Burns School of Medicine, shared an article on X:
“Exciting Update!
Our meta-analysis on SGLT2 inhibitors in cancer patients receiving anthracycline—first presented at ASCO24 now available in ecancer!
Key Findings:
SGLT2 inhibitors significantly reduce all-cause mortality in cancer patients with anthracycline therapy!
No significant effect on heart failure exacerbation risk.
What’s next?
Exciting ongoing trials could change the game!
- PROTECT Trial (NCT06341842) – Could SGLT-2 Inhibitors Protect Against Chemo-Induced Cardiotoxicity?
- EMPACT Study (NCT05271162) – Can Empagliflozin Prevent Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy?
- PROTECTAA Trial (NCT06304857) – Can Dapagliflozin Prevent Cardiotoxicity in Breast Cancer Patients on Anthracycline?
- Could SGLT2 inhibitors become standard therapy for anthracycline-treated cancer patients?
Stay tuned!”
Effect on cardiovascular outcome of sodium-glucose co-transporter-2 (SGLT2) inhibitors among patients with cancer treated with anthracycline: A systematic review and meta-analysis.
Authors: Chalothorn Wannaphut, et al.
Sakditad “Tew” Saowapa, Oncologist at UI Holden Comprehensive Cancer Center, reshared the post on X, adding:
“This is such an amazing job Chalothorn “Sai” Wannaphut!
Thanks for including me and driving the field of oncology forward.
Exciting Update!
Our meta-analysis on SGLT2 inhibitors in cancer patients receiving anthracycline.
First presented at ASCO24 now available in ecancer!”
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023